Molybdenum is an essential trace mineral that activates enzymes clearing sulfites and genetic-material waste. An ordinary diet supplies more than enough, and extra offers no proven benefit to someone already sufficient. Longevity and cancer links rest on geographic patterns tangled with other factors. Overdoing it strips copper and can trigger gout-like symptoms. Sufficiency, not supplementation, is what matters. (Full Review)

Protocol

Primary Approach

Dietary sufficiency

Varied diet delivers well above the 45 mcg/day requirement; no supplementation warranted for most

Supplemental Dose

45–150 mcg/day

Integrative use for sulfite sensitivity; occasionally up to ~500 mcg/day; not trial-backed

Form & Timing

Molybdenum glycinate or sodium molybdate

Single daily dose, with or without food; all forms 85–93% absorbed

Time to effect

Deficiency Correction

Days to weeks

Sulfite handling and deficiency symptoms reverse after repletion

Sulfite Sensitivity

Weeks

Short integrative trial with a defined stopping point

Replete Adults

No perceptible effect

No deficit to correct, so no benefit expected

Benefits

High: Prevents sulfite accumulation and supports sulfur–amino-acid metabolism; completes purine breakdown for uric-acid formation

Medium: Improved tolerance to dietary sulfites; lower prevalence of high uric acid at population level

Low: Reduced esophageal cancer risk in molybdenum-poor regions; protection against dental caries

Speculative: Association with exceptional longevity; insulin-mimetic and blood-pressure effects; nitric-oxide generation via molybdenum enzymes

Contraindications

Gout or hyperuricemia

Wilson's disease on copper-lowering therapy (except under specialist direction)

Gallstones

Reduced kidney function (eGFR <60 mL/min/1.73 m²)

Pregnancy or breastfeeding beyond the 50 mcg requirement

Diagnosed copper deficiency

Key Interactions

Copper supplements and copper-rich regimens

Prescription copper-lowering drugs (tetrathiomolybdate/ALXN1840, penicillamine, trientine)

Gout drugs / xanthine-oxidase inhibitors (allopurinol, febuxostat)

Acetaminophen and other aldehyde-oxidase substrates

High-sulfur intake (sulfite-preserved foods, high-dose sulfur-amino-acid or MSM supplements)

Additive copper-lowering supplements (high-dose zinc)

Risk & Side Effects

High: Copper depletion and copper–molybdenum antagonism

Medium: Gout-like syndrome and elevated uric acid at high intake

Low: Acute neuro-psychiatric toxicity from megadose supplements; reduced fertility and growth signals

Speculative: Bone and connective-tissue effects; interference with drug metabolism

Monitoring

Marker	Target	Why
Serum copper	80–120 mcg/dL	Detects molybdenum-driven copper depletion
Ceruloplasmin	20–35 mg/dL	Confirms functional copper status
Serum uric acid	3.5–5.5 mg/dL	Flags molybdenum-related hyperuricemia/gout risk
Complete blood count	Hgb >13 (men) / >12 (women) g/dL; normal neutrophils	Catches anemia/neutropenia from copper deficiency
Plasma/serum molybdenum	~0.3–2.0 ng/mL	Confirms excess exposure in suspected toxicity

Cadence: Baseline, then ~8–12 weeks, then every 6–12 months during continued use

Qualitative Assessment

No new joint pain or gout flares during use
Stable energy; no new fatigue, pallor, or easy bruising
For a sulfite-sensitivity trial: fewer flushing, wheezing, or headache reactions
No cognitive or mood changes

Molybdenum for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment